Financials
| Final Audited Results for Year Ended 30 September | Dec. 15, 2023 |
| Interim Results for the Six Months Ended 31 March | May. 17, 2023 |
| Final Results for the Year Ended 30 September 2022 | Dec. 20, 2022 |
| Final Results for the Year Ended 30 September 2022 | Dec. 20, 2022 |
| Interim Results for the Six Months Ended 31 March | Jun. 23, 2022 |
| Interim Results for the Six Months Ended 31 March | Jun. 23, 2022 |
| Final Audited Results and Operational Update | Jan. 27, 2022 |
Proxies
| Result of AGM | Mar. 14, 2024 |
| Notice of AGM | Feb. 16, 2024 |
| Result of Annual General Meeting | Mar. 14, 2023 |
| Result of Annual General Meeting | Mar. 14, 2023 |
| Notice of AGM | Feb. 15, 2023 |
| Notice of AGM | Feb. 15, 2023 |
| Result of AGM | Mar. 08, 2022 |
Ownership Update
| Share Purchases by a PDMR | Apr. 30, 2024 |
| Share Purchases by PDMR’s | Apr. 30, 2024 |
| TR-1: Notification of major holdings | Apr. 22, 2024 |
| Share Purchases by a Director | Apr. 18, 2024 |
| Share Purchase by a Director | Apr. 12, 2024 |
| TR-1: Notification of major holdings | Apr. 08, 2024 |
| New Grant of Options | Feb. 23, 2024 |
Announcements
| Redx Reports Encouraging Zamaporvint Phase 2 Data | Jun. 28, 2024 |
| Redx to Present Zamaporvint Phase2 Data at ESMO GI | Jun. 20, 2024 |
| Update on AIM Delisting | Apr. 29, 2024 |
| Result of GM, Cancellation of Admission to Trading | Apr. 19, 2024 |
| Update on Broking Arrangements | Apr. 10, 2024 |
| Proposed Cancellation of Admission to Trading | Apr. 02, 2024 |
| First Participant Dosed in Phase 1 Trial of RXC008 | Feb. 28, 2024 |